In summary, the findings of our study contribute valuable information on the potential utility of plasma levels of NfL, GFAP, GDF15, and FGF21 as biomarkers to assess the severity of CMT. The gene discussed is NEFL; the disease is Charcot-Marie-Tooth disease.